Activity of the potent dual Abl/Src tyrosine kinase inhibitor FB2 against Bcr-Abl positive cell lines in vitro and in vivo

Leukemia Research

Volumn 35, Issue 2, 2011, Pages 237-242

  Yuan, Xia ^a   Zhang, Yi ^a   Zhang, Haijing ^a   Jin, Jing ^a   Li, Xiangyan ^a   Liu, He ^a   Feng, Zhiqiang ^a   Chen, Xiaoguang ^a  

^a INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Bcr Abl; Chronic myelogenous leukemia; Imatinib; Inhibitor; Resistance; Src

Indexed keywords

ABELSON KINASE; BCR ABL PROTEIN; DASATINIB; FB2; IMATINIB; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RESEARCH; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG POTENCY; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GENE EXPRESSION REGULATION; GENE MUTATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MITOSIS INHIBITION; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; WILD TYPE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SEPARATION; DRUG RESISTANCE, NEOPLASM; FEMALE; FLOW CYTOMETRY; FUSION PROTEINS, BCR-ABL; HUMANS; IMMUNOBLOTTING; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASMS, EXPERIMENTAL; PROTEIN KINASE INHIBITORS; PYRIMIDINES; SRC-FAMILY KINASES; THIAZOLES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 78751703419     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.07.041     Document Type: Article

References (33)

1. Rowley J.D. A new consistent abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973, 243:290-293.
2. Wong S., Witte O.N. The BCR-ABL story: bench to bedside and back. Annu Rev Immunol 2004, 22:247-306.
3. Druker B.J., Guilhot F., O'Brien S.G., Gathmann I., Kantarjian H., Gattermann N., et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006, 355(23):2408-2417.
4. Graham S.M., Jorgensen H.G., Allan E., Pearson C., Alcorn M.J., Richmond L., et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002, 99(1):319-325.
5. Marley S.B., Deininger M.W., Davidson R.J., Goldman J.M., Gordon M.Y. The tyrosine kinase inhibitor STI571, like interferon-alpha, preferentially reduces the capacity for amplifi{ligature}cation of granulocyte-macrophage progenitors from patients with chronic myeloid leukemia. Exp Hematol 2000, 28(5):551-557.
6. Melo J.V., Chuah C. Resistance to imatinib mesylate in chronic myeloid leukemia. Cancer Lett 2007, 249(2):121-132.
7. Litzow M.R. Imatinib resistance: obstacles and opportunities. Arch Pathol Lab Med 2006, 130(5):669-679.
8. Mauro M.J., Deininger M.W. Chronic myeloid leukemia in 2006: a perspective. Haematologica 2006, 91(2):152.
9. Apperley J.F., Part I. Mechanisms of resistance to Imatinib in chronic myeloid leukaemia. Lancet Oncol 2007, 8(11):1018-1029.
10. Jabbour E., Kantarjian H., Jones D., Talpaz M., Bekele N., O'Brien S., et al. Frequency and clinical signifi{ligature}cance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 2006, 20(10):1767-1773.
11. Wu J., Meng F., Kong L.Y., Peng Z., Ying Y., Bornmann W.G., et al. Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase. J Natl Cancer Inst 2008, 100(13):926-939.
12. Golas J.M., Arndt K., Etienne C., Lucas J., Nardin D., Gibbons J., et al. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res 2003, 63(2):375-381.
13. Shah N.P., Tran C., Lee F.Y., Chen P., Norris D., Sawyers C.L. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004, 305(5682):399-401.
14. Niwa T., Asaki T., Kimura S. NS-187(INNO-406), a Bcr-Abl/Lyn dual tyrosine kinase inhibitor. Anal Chem Insights 2007, 2:93-106.
15. Liu H., Li H., Feng Z., Tai J., Meng Y., Wang H., et al. Activity of FB2, a novel dual Abl/Src tyrosine kinase inhibitor, against imatinib-resistant chronic myeloid leukemia in vivo and in vitro. Leuk Lymphoma 2009, 50(3):437-446.
16. Li S., Ilaria R.L., Million R.P., Daley G.Q., Van Etten R.A. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J Exp Med 1999, 189(9):1399-1412.
17. Johnson J.I., Decker S., Zaharevitz D., Rubinstein L.V., Venditti J.M., Schepartz S., et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer 2001, 84(10):1424-1431.
18. Druker B.J., Tamura S., Buchdunger E., Ohno S., Segal G.M., Fanning S., et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996, 2(5):561-566.
19. Beran M., Cao X., Estrov Z., Jin G., O'Brien S., Talpaz M., et al. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cell expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148). Clin Cancer Res 1998, 4(7):1661-1672.
20. Gambacorti-Passerini C., le Coutre P., Mologni L., Fanelli M., Bertazzoli C., Marchesi E., et al. Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. Blood Cells Mol Dis 1997, 23(3):380-394.
21. Brave M., Goodman V., Kaminskas E., Farrell A., Timmer W., Pope S., et al. Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate. Clin Cancer Res 2008, 14(2):352-359.
22. Lombardo L.J., Lee F.Y., Chen P., Norris D., Barrish J.C., Behnia K., et al. Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino) thiazole-5-carboxamide(BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004, 47(27):6658-6661.
23. Shah N.P., Sawyers C.L. Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias. Oncogene 2003, 22(47):7389-7395.
24. O'Hare T., Eide C.A., Deininger M.W. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 2007, 110(7):2242-2249.
25. Shah N.P., Nicoll J.M., Nagar B., Gorre M.E., Paquette R.L., Kuriyan J., et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002, 2(2):117-125.
26. Roche-Lestienne C., Soenen-Cornu V., Grardel-Duflos N., Laï J.L., Philippe N., Facon T., et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 2002, 100(3):1014-1018.
27. Kimuta S., Naito H., Segawa H., Kuroda J., Yuasa T., Sato K., et al. NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood 2005, 106(12):3984-4054.
28. Li S. Src kinase signaling in leukaemia. Int J Biochem Cell Biol 2007, 39(7-8):1483-1488.
29. Danhauser-Riedl S., Warmuth M., Druker B.J., Emmerich B., Hallek M. Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells. Cancer Res 1996, 56(15):3589-3596.
30. Gardai S., Whitlock B.B., Helgason C., Ambruso D., Fadok V., Bratton D., et al. Activation of SHIP by NADPH oxidase-stimulated Lyn leads to enhanced apoptosis in neutrophils. J Biol Chem 2002, 277(7):5236-5246.
31. Hu Y., Swerdlow S., Duffy T.M., Weinmann R., Lee F.Y., Li S. Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice. Proc Natl Acad Sci U S A 2006, 103(45):16870-16875.
32. Grana X., Reddy P. Cell cycle control in mammalian cells: role of cyclins, cyclin-dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CDKIs). Oncogene 1995, 11(2):211-219.
33. Das G.C., Holiday D., Gallardo R., Haas C. Taxol-induced cell cycle arrest and apoptosis: dose-response relationship in lung cancer cells of different wild-type p53 status and under isogenic condition. Cancer Lett 2001, 165(2):147-153.